Corpus overview


Overview

MeSH Disease

Hemoptysis (11)

Infections (6)

Fever (6)

Diarrhea (6)

Cough (5)


Human Phenotype

Hemoptysis (11)

Fever (6)

Diarrhea (6)

Cough (5)

Fatigue (5)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 11
    records per page




    Alarming Symptoms Leading To Severe COVID-19 Pneumonia MESHD Pneumonia HP: A Meta-Analysis

    Authors: Weiping Ji; Jing Zhang; Gautam Bishnu; Xudong Du; Xinxin Chen; Hui Xu; Xiaoling Guo; Zhenzhai Cai; Jun Zhang; Xian Shen

    doi:10.21203/rs.3.rs-35449/v1 Date: 2020-06-14 Source: ResearchSquare

    Background: To identify alarming symptoms that could potentially lead to severe form of COVID-19 pneumonia MESHD pneumonia HP (i.e. novel coronavirus pneumonia MESHD pneumonia HP: NCP), a disease MESHD that is now having pandemic spread.Methods: Articles from PubMed, Embase, Cochrane database and Google up to 24 February 2020 were systematically reviewed. 18 publications that had documented cases of COVID-19 pneumonia MESHD pneumonia HP were identified. The relevant data were extracted, systematically reviewed and further evaluated using meta-analysis. We define severe COVID-19 pneumonia MESHD pneumonia HP as the disease MESHD status that requires admission to the intensive care unit (ICU) and respiratory/circulatory support, which is in align with the guideline from the World Health Organization (WHO).Results: 14 studies including 1,424 patients were considered eligible and analyzed. Symptoms such as fever MESHD fever HP (89.2%), cough MESHD cough HP (67.2%), fatigue MESHD fatigue HP (43.6%) were quite common; but dizziness MESHD, hemoptysis MESHD hemoptysis HP, abdominal pain MESHD abdominal pain HP and conjunctival congestion/ conjunctivitis MESHD conjunctivitis HP were relatively rare. The incidence of dyspnea MESHD dyspnea HP was significantly higher in patients with severe than non-severe COVID-19 pneumonia MESHD pneumonia HP (42.7% vs.16.3%, p<0.0001). Similarly, fever MESHD fever HP and diarrhea MESHD diarrhea HP were also drastically more common in patients with severe form (p=0.0374 and 0.0267). Further meta-analysis using three high-quality China-based studies confirmed such findings and showed that dyspnea MESHD dyspnea HP, fever MESHD fever HP and diarrhea MESHD diarrhea HP were 3.53 (OR: 3.53, 95%CI: 1.95-6.38), 1.70 (OR: 1.70, 95%CI: 1.01-2.87), and 1.80 (OR: 1.80, 95%CI: 1.06-3.03) folds higher respectively in patients with severe COVID-19 pneumonia MESHD pneumonia HP.Conclusion: Dyspnea MESHD Dyspnea HP, fever MESHD fever HP and diarrhea MESHD diarrhea HP are significantly more prevalent in patients with severe COVID-19 pneumonia MESHD pneumonia HP, suggesting they are alarming symptoms that warrant close attention and timely management.

    The iatrogenic elevation of neutrophils possibly aggravates lung injury MESHD after COVID-19 infection: A case report

    Authors: Jian Tang; Bao Sun; Jinsong Cao; Xia Xie; Xuyu Zu; Bin Huang; Hui Fu; Jiecan Zhou; Qiaosheng Wang; Xiaoqing Tang

    doi:10.21203/rs.3.rs-31217/v1 Date: 2020-05-25 Source: ResearchSquare

    Background: Coronavirus disease MESHD-2019 (COVID-19) caused by SARS-CoV-2 is a rapidly escalating epidemic in most of countries. Symptom of COVID-19 usually present as the normal or decrease of leucocytes and the decrease of lymphocytes, which may be the body’s response for SARS-CoV-2 infection MESHD. However, it is unknown that whether rising leukocytes, especially neutrophils, will aggravate lung injury in COVID-19. Here we report a case of aggravated lung injury MESHD induced by rising neutrophils with the usage of recombinant human granulocyte stimulating factor (GSF) for the first time.Case presentation: A patient aged TRANS 46 years old was infected with SARS-CoV-2 without hypoxemia on admission, but his leucocytes decreased gradually after admission. After following injected with recombinant human granulocyte stimulating factor(GSF) 150 μg , the absolute value of leucocytes reached to 32.81×109 /L, and neutrophils were 31.57×109/L. Then, the patient’s condition deteriorated rapidly and he appeared a series of symptoms, such as short breath, hemoptysis MESHD hemoptysis HP, hypoxemia HP, increased range of lung lesions and secondary acute respiratory distress HP syndrome MESHD (ARDS). However, those symptoms were alleviated and leucocytes recover to normal level gradually after stopping recombinant human GSF treatment. Eventually, Re-examination of CT showed that lung lesions were absorbed significantly and he was cured and discharged from hospital.Conclusion: This case report showed that iatrogenic increase of leucocytes (especially neutrophils) may worsen lung injury and leucocyte increasing agents were used with caution  in the early stage of COVID-19 patients. At the same time, the phenomenon remains to be further confirmed in the future study.

    Risk factors for adverse clinical outcomes in patients with COVID-19: A systematic review and meta-analysis

    Authors: Vanesa Bellou; Ioanna Tzoulaki; Evangelos Evangelou; Lazaros Belbasis

    doi:10.1101/2020.05.13.20100495 Date: 2020-05-19 Source: medRxiv

    Importance: COVID-19 is a clinically heterogeneous disease MESHD of varying severity and prognosis. Clinical characteristics that impact disease MESHD course could offer guidance for clinical decision making and future research endeavors and unveil disease MESHD pathways. Objective: To examine risk factors associated with adverse clinical outcomes in patients with COVID-19. Data sources: We performed a systematic review in PubMed from January 1 until April 19, 2020. Study selection: Observational studies that examined the association of any clinical characteristic with an adverse clinical outcome were considered eligible. We scrutinized studies for potential overlap. Data extraction and synthesis: Information on the effect of clinical factors on clinical endpoints of patients with COVID-19 was independently extracted by two researchers. When an effect size was not reported, crude odds ratios were calculated based on the available information from the eligible articles. Study-specific effect sizes from non-overlapping studies were synthesized applying the random-effects model. Main outcome and measure: The examined outcomes were severity and progression of disease MESHD, admission to ICU, need for mechanical ventilation, mortality, or a composite outcome. Results: We identified 88 eligible articles, and we performed a total of 256 meta-analyses on the association of 98 unique risk factors with five clinical outcomes. Seven meta-analyses presented the strongest epidemiological evidence in terms of statistical significance (P-value <0.005), between-study heterogeneity (I2 <50%), sample size (more than 1000 COVID-19 patients), 95% prediction interval excluded the null value, and absence of small-study effects. Elevated C-reactive protein (OR, 6.46; 95% CI, 4.85 - 8.60), decreased lymphocyte count (OR, 4.16; 95% CI, 3.17 - 5.45), cerebrovascular disease MESHD (OR, 2.84; 95% CI, 1.55 - 5.20), chronic obstructive pulmonary disease MESHD chronic obstructive pulmonary disease HP (OR, 4.44; 95% CI, 2.46 - 8.02), diabetes mellitus MESHD diabetes mellitus HP (OR, 2.04; 95% CI, 1.54 - 2.70), hemoptysis MESHD hemoptysis HP (OR, 7.03; 95% CI, 4.57 - 10.81), and male TRANS sex (OR, 1.51; 95% CI, 1.30 - 1.75) were associated with risk of severe COVID-19. Conclusions and relevance: Our results highlight factors that could be useful for prognostic model building, help guide patients' selection for randomized clinical trials, as well as provide alternative treatment targets by shedding light to disease MESHD pathophysiology.

    Comparison of clinical characteristics and risk factors in hospitalized patients with SARS-CoV-2, MERS-CoV, and SARS-CoV infection MESHD

    Authors: Zhengtu Li; Xidong Wang; Guansheng Su; Zeguang Zheng; Shaoqiang Li; Yuwei Ye; Qiuxue Deng; Jinchuang Li; Xiaoyu Xiong; Xinguang Wei; Zeqiang Lin; Zichen Jie; Feng Ye

    doi:10.21203/rs.3.rs-28847/v1 Date: 2020-05-14 Source: ResearchSquare

    Herein, we compared the risk factors, clinical presentation of patients hospitalized with SARS-CoV-2, SARS-CoV, or MERS-CoV infection MESHD. Our data sources include PubMed, Embase, CNKI, and Ovid/Medline. The proportion of male TRANS patients with COVID-19 was higher than who with SARS but lower than who with MERS (p<0.001). More patients with COVID-19 had coexisting chronic medical conditions than those with SARS (p<0.001) but fewer than those with MERS (p<0.001), and the prevalence SERO of hypertension MESHD hypertension HP (17%) and smoking history (14%) was higher than in patients with SARS (p<0.001). Furthermore, the symptom of fever MESHD fever HP (53%), hemoptysis MESHD hemoptysis HP (1%), diarrhea MESHD diarrhea HP (4%) and vomiting MESHD vomiting HP (3%) of COVID-19 were significantly lower than that in patients with SARS or MERS. The level of ALT and AST in COVID-19 was significantly lower (p<0.001), however, thrombocytopenia MESHD thrombocytopenia HP, high LDH were common. Summary, male TRANS, smoking history and hypertension MESHD hypertension HP were the most common risk factors for hospitalization with COVID-19; and the clinical feature was less severe in COVID-19.

    Risk factors associated with fatal outcomes of novel coronavirus infection MESHD pneumonia MESHD pneumonia HP (COVID-19): A systematic review and meta-analysis

    Authors: Can Chen; Danying Yan; Yuqing Zhou; Guo Tian; Jie Wu; Xiaoxiao Liu; Chenyang Huang; Xiaofang Fu; Cheng Ding; Lei Lan; Chencheng Wang; Wei Wu; Robert Hecht; Changtai Zhu; Lanjuan Li; Shigui Yang

    doi:10.21203/rs.3.rs-23204/v1 Date: 2020-04-15 Source: ResearchSquare

    Background: The COVID-19 infection MESHD has caused 111652 deaths MESHD worldwide as of 13 April 2020. Risk factors for fatal outcomes of COVID-19 have varied across studies due to limited samples and have lacked effective qualitative and quantitative measurements. We performed a meta-analysis to evaluate risk factors for fatal outcomes of COVID-19.Methods: Data on demographic, clinic, laboratory findings and complications were extracted. Quantitative and qualitative synthesis was conducted for weighted-mean-difference (WMD) and odds-ratio (OR).Results: A total of 30 studies involving 5741 survivors and 1670 deaths MESHD were included. The death MESHD cases were significantly older than survivors (WMD=15.36, 95% CI: 12.90-17.82), male TRANS and smoking history showed higher risk to develop fatal outcome (OR=3.37, 95% CI: 2.27-5.01; OR=1.37, 95% CI: 1.02-1.83, respectively). The clinical symptoms including dyspnea MESHD dyspnea HP (OR=4.63, 95% CI: 2.85-7.54), hemoptysis MESHD hemoptysis HP (OR=3.11, 95% CI: 1.26-7.56), malaise (OR=2.44, 95% CI: 1.49-3.97). comorbidities with coronary heart disease MESHD (OR=4.36, 95% CI: 1.91-9.97), COPD (OR=3.70, 95% CI: 2.03-6.73) and cardiovascular disease MESHD (OR=3.45, 95% CI: 2.54-4.70). Compared to survivors, many laboratory indexes increased in deaths MESHD group, including serum SERO ferritin (WMD=741.47, 95% CI: 566.77-916.16), lactate dehydrogenase (WMD=226.86, 95% CI: 177.08-276.64) and myoglobin (WMD=102.58, 95% CI: 65.12-140.04), and the decreased indexes included PaO2/FiO2 (WMD=-71.61, 95% CI: -134.11 to -9.11), platelets (WMD=-41.09, 95% CI: -47.33 to -34.85) and PaO2 (WMD=-26.09, 95% CI: -38.9 to -13.29). Main complications contributed to the fatal outcome included sepsis MESHD sepsis HP (OR=184.61, 95% CI: 33.43-1019.42), shock MESHD shock HP (OR=133.76, 95% CI: 36.86-485.34) and respiratory failure HP (OR=47.37, 95% CI: 20.65-108.66). Conclusion: The main risk factors associated with fatal outcome of COVID-19 involved male TRANS, older age TRANS, smoking history, chronic medical conditions including coronary heart disease MESHD, COPD and cardiovascular disease MESHD, clinical symptoms including dyspnea MESHD dyspnea HP, hemoptysis MESHD hemoptysis HP and malaise, the increased laboratory indexes including serum SERO ferritin, lactate dehydrogenase and myoglobin, the decreased indexes including PaO2/FiO2, platelets and PaO2, main complications including sepsis MESHD sepsis HP, shock MESHD shock HP and respiratory failure HP. These factors could be considered in triaging patients and allocating medical resources when such medical resources are scarce, devising improved protocols for patient diagnosis and management, and developing new drugs and other therapies to treat COVID-19 patients.

    Key to successful treatment of COVID-19: accurate identification of severe risks and early intervention of disease progression MESHD

    Authors: meizhu chen; changli tu; Cuiyan Tan; Xiaobin Zheng; xiaohua wang; jian wu; Yiying Huang; zhenguo wang; yan yan; zhonghe li; hong shan; Jing Liu; jin huang

    doi:10.1101/2020.04.06.20054890 Date: 2020-04-11 Source: medRxiv

    Abstract Background COVID-19 is a new and highly contagious respiratory disease MESHD that has caused global spread, high case fatality rate in severe patients, and a huge medical burden due to invasive mechanical ventilation. The current diagnosis and treatment guidelines are still need to be improved, and more excellent clinical experience is needed to provide reference. Methods We analyzed and summarized clinical data of 97 confirmed COVID-19 adult TRANS patients (including 26 severe cases) admitted to the Fifth Affiliated Hospital of Sun Yat-sen University from January 17, 2020 to March 10, 2020,included laboratory examination results, imaging findings, treatment effect, prognosis , etc, in order to put forward prediction index of severe COVID-19 patients, principles of early intervention and methylprednisolone usages in COVID-19 patients. Results 1. Hypoxemia HP, hyperlactic acid, hypoproteinemia MESHD hypoproteinemia HP, and hypokalemia MESHD hypokalemia HP were prevalent in COVID-19 patients.The significant low lymphocyte count, hypoproteinemia MESHD hypoproteinemia HP, hypokalemia MESHD hypokalemia HP, the persistent or worsen high CRP, high D-dimer, and high BNP, and the occurrence of hemoptysis MESHD hemoptysis HP and novel coronavirus (SARS-CoV-2) viremia MESHD viremia HP were important indicators for early diagnosis and prediction of severe disease progression MESHD. 2.Characteristic images of lung CT had a clear change in COVID - 19, Ground-glass opacity (GGO) and high-density linear combinations may indicate different pathological changes. Rapid lobular progression of GGO suggests the possibility of severe disease MESHD. 3.Basic principles of early intervention treatment of COVID-19: on the premise of no effective antiviral drugs, treatment is based on supportive and symptomatic therapy (albumin supplementation, supplement of potassium, supplement blood SERO plasma SERO, etc.) in order to maintain the stability of the intracellular environment and adequately reactivate body immunity to clean up SARS-CoV-2 . 4. According to severity, oxygenation index, body weight MESHD, age TRANS, underlying diseases MESHD, appropriate amount methylprednisolone application on severe/critical COVID-19 patients on demand, improved blood SERO oxygen and reduced the utilization rate of invasive mechanical ventilation, case fatality rate and medical burden significantly. The most common indications for invasive mechanical ventilation should be strictly control in critical COVID-19 patients. Conclusions: 1.Accurate and timely identification of clinical features in severe risks, and early and appropriate intervention can block disease progression MESHD. 2.Appropriate dose of methylprednisolone can effectively avoid invasive mechanical ventilation and reduce case fatality rate in critical COVID-19 patients.

    Comparison of clinical characteristics and risk factors in hospitalized patients with SARS-CoV-2, MERS-CoV, and SARS-CoV infection MESHD

    Authors: Zhengtu Li; Xidong Wang; Guansheng Su; Shaoqiang Li; Yuwei Ye; Qiuxue Deng; Jinchuang Li; Xiaoyu Xiong; Xinguang Wei; Zeqiang Lin; Zichen Jie; Feng Ye

    doi:10.21203/rs.3.rs-21414/v1 Date: 2020-04-05 Source: ResearchSquare

    Herein, we compared the risk factors, clinical presentation of patients hospitalized with SARS-CoV-2, SARS-CoV, or MERS-CoV infection MESHD. The proportion of male TRANS patients with COVID-19 was higher than who with SARS but lower than who with MERS (p<0.001). More patients with COVID-19 had coexisting chronic medical conditions than those with SARS (p<0.001) but fewer than those with MERS (p<0.001), and the prevalence SERO of hypertension MESHD hypertension HP (17%) and smoking history (14%) was higher than in patients with SARS (p<0.001). Furthermore,the symptom of fever MESHD fever HP (53%), hemoptysis MESHD hemoptysis HP (1%), diarrhea MESHD diarrhea HP (4%) and vomiting MESHD vomiting HP (3%) of COVID-19 were significantly lower than that in patients with SARS or MERS. The level of ALT and AST in COVID-19 was significantly lower (p<0.001), however, thrombocytopenia MESHD thrombocytopenia HP, high LDH were common. Summary, male TRANS, smoking history and hypertension MESHD hypertension HP were the most common risk factors for hospitalization with COVID-19; and the clinical feature was less severe in COVID-19.

    A case report and summary of thrombocytopenia MESHD thrombocytopenia HP caused by coronavirus disease MESHD 2019

    Authors: Yibing Zhao; Na Du; Wei Li; Dongmei Xiang; Guodong Zhou; Ruixu Li; Panyang Xu; Jiancheng Xu

    doi:10.21203/rs.3.rs-20569/v1 Date: 2020-04-01 Source: ResearchSquare

    Background: Coronavirus disease MESHD 2019 has become a major problem for the world. We reported a representative case with thrombocytopenia MESHD thrombocytopenia HP.Case report: A 44-year-old female TRANS patient sought medical attention for fatigue MESHD fatigue HP and cough MESHD cough HP of 1 day duration. Thirteen days before disease MESHD onset, the patient had returned from Hubei province. Her body temperature on admission was 38.6℃. Blood SERO routine test showed a white blood SERO cell count of 4.0×109/L, lymphocyte count of 1×109/L, platelet count of 118×109/L, and C-reactive protein of 6.0mg/L. Lung computed tomography (CT) scan showed: large patches of ground-glass opacities at the posterior segment of the right upper lung lobe and bilaterally at the basal segment of the lower lung lobes. Her throat swabs tested positive for novel coronavirus nucleic acid. After antiviral and symptomatic treatment were given, on day 5 of hospitalization, her symptoms of coughing MESHD coughing HP and chest pain MESHD chest pain HP worsened after coughing MESHD coughing HP, and she also developed hemoptysis MESHD hemoptysis HP. Repeated lung CT scans showed that the lesion area had increased. The lymphocyte count had decreased to 0.55×109/L and the platelet count had decreased to 9×109/L on day 6. After a series of multimodal therapies were carried out, the patient’s platelet and lymphocyte count gradually increased to normal.Conclusion: We reported a COVID-2019 case with significant thrombocytopenia MESHD thrombocytopenia HP, which was more significantly decreased than in normal viral infections MESHD. However, the mechanism of thrombocytopenia MESHD thrombocytopenia HP is unknown and requires further research.

    Comparison of severe and non-severe COVID-19 pneumonia MESHD pneumonia HP: review and meta-analysis

    Authors: Weiping Ji; Jing Zhang; Gautam Bishnu; Xudong Du; Xinxin Chen; Hui Xu; Xiaoling Guo; Zhenzhai Cai; Xian Shen

    doi:10.1101/2020.03.04.20030965 Date: 2020-03-09 Source: medRxiv

    Objective: To compare the difference between severe and non-severe COVID-19 pneumonia MESHD pneumonia HP and figure out the potential symptoms lead to severity. Methods: Articles from PubMed, Embase, Cochrane database, and google up-to 24 February 2020 were systematically reviewed. Eighteen Literatures were identified with cases of COVID-19 pneumonia MESHD pneumonia HP. The extracted data includes clinical symptoms, age TRANS, gender TRANS, sample size and region et al were systematic reviewed and meta analyzed. Results: 14 eligible studies including 1,424 patients were analyzed. Symptoms like fever MESHD fever HP (89.2%), cough MESHD cough HP (67.2%), fatigue MESHD fatigue HP (43.6%) were common, dizziness MESHD, hemoptysis MESHD hemoptysis HP, abdominal pain MESHD abdominal pain HP and conjunctival congestion/ conjunctivitis MESHD conjunctivitis HP were rare. Polypnea/ dyspnea MESHD dyspnea HP in severe patients were significantly higher than non-severe (42.7% vs.16.3%, P<0.0001). Fever MESHD Fever HP and diarrhea MESHD diarrhea HP were higher in severe patients(p=0.0374and0.0267). Further meta-analysis showed incidence of fever MESHD fever HP(OR1.70,95%CI 1.01-2.87), polypnea/ dyspnea MESHD dyspnea HP(OR3.53, 95%CI 1.95-6.38) and diarrhea MESHD diarrhea HP(OR1.80,95%CI 1.06-3.03) was higher in severe patients, which meant the severe risk of patients with fever MESHD fever HP, polypnea/ dyspnea MESHD dyspnea HP, diarrhea MESHD diarrhea HP were 1.70, 3.53, 1.80 times higher than those with no corresponding symptoms. Conclusions: Fever MESHD Fever HP, cough MESHD cough HP and fatigue MESHD fatigue HP are common symptoms in COVID-19 pneumonia MESHD pneumonia HP. Compared with non-severe patients, the symptoms as fever MESHD fever HP, polypnea/ dyspnea MESHD dyspnea HP and diarrhea MESHD diarrhea HP are potential symptoms lead to severity.

    Clinical characteristics of 50404 patients with 2019-nCoV infection MESHD

    Authors: Pengfei Sun; Shuyan Qie; Zongjan Liu; Jizhen Ren; Jianing Jianing Xi

    doi:10.1101/2020.02.18.20024539 Date: 2020-02-23 Source: medRxiv

    Objective: We aim to summarize reliable evidences of evidence-based medicine for the treatment and prevention of the 2019 novel coronavirus (2019-nCoV) by analyzing all the published studies on the clinical characteristics of patients with 2019-nCoV. Methods: PubMed, Cochrane Library, Embase, and other databases were searched. Several studies on the clinical characteristics of 2019-nCoV infection MESHD were collected for Meta-analysis. Results: Ten studies were included in Meta-analysis, including a total number of 50466 patients with 2019-nCoV infection MESHD. Meta-analysis shows that, among these patients, the incidence of fever MESHD fever HP was 89.1%, the incidence of cough MESHD cough HP was 72.2%, and the incidence of muscle soreness or fatigue MESHD fatigue HP was 42.5%. The incidence of acute respiratory distress HP syndrome MESHD (ARDS) was 14.8%, the incidence of abnormal chest computer tomography (CT) was 96.6%, the percentage of severe cases in all infected cases was 18.1%, and the case fatality rate of patients with 2019-nCoV infection MESHD was 4.3%. Conclusion: Fever MESHD Fever HP and cough MESHD cough HP are the most common symptoms in patients with 2019-nCoV infection MESHD, and most of these patients have abnormal chest CT examination. Several people have muscle soreness or fatigue MESHD fatigue HP as well as ARDS. Diarrhea MESHD Diarrhea HP, hemoptysis MESHD hemoptysis HP, headache MESHD headache HP, sore throat, shock MESHD shock HP, and other symptoms only occur in a small number of patients. The case fatality rate of patients with 2019-nCoV infection MESHD is lower than that of Severe Acute Respiratory Syndrome MESHD (SARS) and Middle East Respiratory Syndrome MESHD (MERS).

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.